Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients


Currently, amrubicin is permitted for relapsed small-cell lung carcinoma (SCLC) only in Japan. The efficacy and adverse effects of amrubicin as reported by previous studies varied greatly. The inclusion criterion was a prospective study that was able to provide data for efficacy and safety by the AMR single agent regimen as second-line chemotherapy for a… (More)
DOI: 10.1038/srep18999


5 Figures and Tables